artelo

Artelo Biosciences, a company listed on NASDAQ, announced the private sale of a total of 3,188,407 shares of common stock at a price of $3.45 per share, raising a total of $11 million. Additionally, the company disclosed that it will sell up to 6,376,814 warrants for common stock at a price of $3.20 per share. If the warrants are fully exercised in cash, the total funds raised will be approximately $20.4 million, with the transaction expected to be completed around March 30.According to market news, the latest data from the Strategic Solana Reserve shows that Artelo currently holds 45,883 SOL.

ChainCatcher news, Nasdaq-listed Solana treasury company Artelo Biosciences announced a public offering of 640,924 shares of common stock at a price of $4.4 per share, raising a total of approximately $3 million. Artelo Biosciences is a clinical pharmaceutical company that has previously announced the official launch of a Solana-based digital asset treasury strategy and has invested part of its capital in purchasing SOL tokens, currently holding 45,883 SOL.

ChainCatcher news, according to GlobeNewswire, clinical-stage pharmaceutical company Artelo Biosciences (NASDAQ: ARTL) announced the completion of a $9.475 million private placement, which will be used to initiate a digital asset reserve strategy centered around Solana (SOL). The company becomes the first publicly traded pharmaceutical enterprise to include SOL in its reserve assets.The private placement includes the issuance of common stock (or pre-funded warrants) at a price of $10.45 per share, as well as two tranches of three-year warrants with exercise prices of $10.20 and $50. The transaction is expected to be completed on August 5, 2025.